Autoimmune diseases (ADs) are conditions in which the immune system cannot distinguish self from non-self and, as a result, tissue injury occurs primarily due to the action of various inflammatory mediators. Different immunosuppressive agents are used for the treatment of patients with ADs, but some clinical cases develop resistance to currently available therapies. The proteasome inhibitor bortezomib (BTZ) is an approved agent for first-line therapy of people with multiple myeloma. BTZ has been shown to improve the symptoms of different ADs in animal models and ameliorated symptoms in patients with systemic lupus erythematous, rheumatoid arthritis, myasthenia gravis, neuromyelitis optica spectrum disorder, Chronic inflammatory demyelinating polyneuropathy, and autoimmune hematologic diseases that were nonresponsive to conventional therapies. Proteasome inhibition provides a potent strategy for treating ADs. BTZ represents a proteasome inhibitor that can potentially be used to treat AD patients resistant to conventional therapies.

自身免疫性疾病 (AD) 是免疫系统无法区分自身和非自身的疾病，因此，组织损伤主要是由于各种炎症介质的作用而发生的。不同的免疫抑制剂用于治疗 AD 患者，但一些临床病例对目前可用的疗法产生耐药性。蛋白酶体抑制剂硼替佐米 (BTZ) 是一种获准用于多发性骨髓瘤患者一线治疗的药物。BTZ 已被证明可改善动物模型中不同 AD 的症状，并改善系统性红斑狼疮、类风湿性关节炎、重症肌无力、视神经脊髓炎谱系障碍、慢性炎症性脱髓鞘性多发性神经病和对常规疗法无反应的自身免疫性血液病患者的症状. 蛋白酶体抑制为治疗 AD 提供了有效的策略。BTZ 代表一种蛋白酶体抑制剂，可潜在地用于治疗对常规疗法有抵抗力的 AD 患者。